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Abstract. Epithelial-mesenchymal transition (EMT) is a 
crucial event required for the invasion and progression of 
carcinogenesis, inducing stem-like properties in epithelial 
cells. In the present study, the expression of BMI1, which 
controls self-renewal in stem cells, as well as that of ZEB1, a 
transcription factor that regulates EMT, was evaluated for its 
role in EMT and the carcinogenic processes of tongue squa-
mous cell carcinoma (TSCC). Collagen invasion assays using 
two TSCC cells and 64 tongue specimens (32 carcinomas and 
32 dysplasias) were employed and analyzed in the present 
study. We assessed the protein and mRNA expression levels of 
BMI1, ZEB1, vimentin and E-cadherin in the two cell lines and 
tumor tissues. The protein and mRNA expression of BMI1 and 
ZEB1 occurred at the invasion of TSCC. The elevated levels of 
BMI1 and ZEB1 were accompanied by the downregulation of 
E-cadherin and upregulation of vimentin at the invasive front, 
indicative of EMT in vitro and in vivo. The results showed that 
BMI1 and ZEB1 are important factors in association with the 
promotion of EMT and invasion of TSCC.
Introduction
Head and neck squamous cell carcinoma (HNSCC), including 
oral cancer, is the sixth most prevalent cancer worldwide and 
accounts for ~8-10% of all cancer types in Southeast Asia (1,2). 
Despite improvements in the diagnosis and management of 
HNSCC, long-term survival rates have improved only margin-
ally over the past decade (3). To improve the survival rate in 
HNSCC patients, investigations into the underlying molecular 
and phenotypic events associated with head and neck squamous 
tumorigenesis are necessary. The identification of biomarkers 
for early detection and prognostic stratifications is also needed.
Recent findings have suggested that the persistent survival 
of cancer stem cells (CSCs), also known as tumor-initiating 
cells, may contribute to the aggression and recurrence of 
HNSCC (4-7). These CSCs are key contributors to radio- and 
chemoresistance and are responsible for tumor progression 
and recurrence after conventional therapy (4,8).
Additionally, epithelial-mesenchymal transition (EMT) is 
a key developmental program that is often activated in CSCs 
during cancer development (9,10). The occurrence of EMT 
in cancer cells may lead to a number of changes including 
loss of cell polarity and downregulation of epithelial cell 
markers, loss of cell-cell connections, in addition to gaining 
mesenchymal phenotypes along with genetic/epigenetic modi-
fications of different genes. Published studies suggest a direct 
link between EMT and the gain of CSC-like properties (11). 
This process is thought to be a critical step in the induction of 
tumor metastasis and malignancy (12).
B-lymphoma Moloney murine leukemia virus insertion 
region-1 (BMI1), a member of the polycomb group (PcG) genes, 
is considered to be pivotal in regulating stemness-related genes 
involved in maintaining the self-renewal ability of stem cells 
by promoting chromatin modifications. BMI1 is also known to 
be deregulated in various human types of cancer (13-16). BMI1 
is a prognostic marker in prostate, breast, ovarian, cervical, 
colorectal, lung, esophageal, gastric and nasopharyngeal 
cancer (13,17-24). However, the role of BMI1 in maintaining 
self-renewal and tumorigenicity in HNSCC or HNSCC-derived 
cancer stem cells (CSCs) remains to be clarified.
ZEB1, a member of the zinc-finger transcription factor 
family, is one of the master regulators of EMT that mediates 
invasiveness as well as metastasis in many different types of 
malignant tumors. ZEB1 induces EMT by suppressing the 
expression of E-cadherin and contributing to the progression of 
malignant cancer (25). ZEB1 is a good predictor of prognosis 
in breast, lung, colorectal and esophageal cancer (26-29). 
Extensive studies have revealed that several transcription 
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factors such as ZEB1 function together to regulate the EMT 
program (30). However, the role of ZEB1 in HNSCC remains 
unclear.
In the present study, we studied several biomarkers, BMI1, 
ZEB1, vimentin and E-cadherin associated with EMT in tongue 
squamous cell carcinoma (TSCC) cells and tumor specimens 
to determine their relationship to the invasion and progression 
of these tumors. TSCC accounts for ~60% of oral squamous 
cell carcinoma and clarification of the significance of BMI1 
and ZEB1 in this disease is critical for future therapies.
Materials and methods
Carcinoma cell lines and isolation of fibroblasts. Two 
human TSCC cell lines, Tosca-2S and Tosca-23, and human 
fibroblasts (31) were used. Human fibroblasts were collected 
from human oral specimens; tissues were cultured and the 
migrating fibroblasts were subcultured for 3-10 passages and 
used as stromal cells for this assay.
Collagen gel invasion assay. To conduct the collagen gel 
invasion assay, we used a 3-dimensional collagen gel culture. 
Insert chambers with 8-µm pores were treated and placed in 
six 35-mm culture dishes.
first, a collagen solution was poured into the chambers 
and incubated at 37˚C for 30 min to solidify the gel. Second, 
eight volumes of acid-soluble 0.3% type I collagen solution 
(Cellmatrix type I-A, pH 3.0), one volume of x10 concentrated 
minimum essential medium, and one volume of reconstruc-
tion buffer (2.2 g of sodium bicarbonate and 4.77 g of HEPES 
dissolved in 100 ml of 0.05 N sodium hydroxide) were mixed. 
fibroblasts were added to this solution at a density of 1x105/ml, 
subsequently, 2 ml of this mixture containing fibroblasts was 
added to the chamber on top of the solid collagen-only layer. 
After solidifying, medium was added to the upper and lower 
parts of the well. TSCC cells were then spread on the gel.
The 35-mm plates were observed using a phase-contrast 
microscope on a daily basis. four weeks later, the whole 
collagen gel was fixed with 10% formalin, embedded in 
paraffin, cut into vertical 4-µm sections, deparaffinized and 
stained with hematoxylin and eosin. for immunostaining, 
antigens were retrieved by heating at 120˚C for 20 min, and 
cancer cells were identified with vimentin, E-cadherin, BMI1 
and ZEB1 antibodies.
The linear borderline between the cells and the gel corre-
sponded to the basement membrane. The TSCC cells in the 
stratified layer along the gel or in contact with the basement 
membrane were considered preinvasive, and any downgrowth 
into the gel as invasion.
Tissue samples and patients. Tongue tissue specimens were 
accessed at the Oral Pathology of Showa university from 
1997 to 2011, and were used in the present study. A total of 
47 patients were eligible for inclusion (24 men and 23 women, 
with a median age of 58 years, range 30-83 years). All the 
patients had undergone resection of the tongue primary tumor 
and did not include any patients with distant metastasis or any 
who had received preoperative therapy.
The present study was approved by the Ethics Committee, 
Oral Pathology of Showa university, and adhered to the 
principles in the Declaration of Helsinki. Samples were 
obtained after the patients had provided informed consent 
(permit no. 8, November 2, 2001).
Tongue tissues were surgically resected from the patients 
and hematoxylin and eosin-stained slides were assessed. 
The tissues were frozen in isopentane cooled in liquid 
nitrogen and stored at -80˚C for immunohistochemistry and 
RT-PCR. Sixty-four fresh-frozen samples were collected, of 
which 32 were primary invasive tongue cancers (15 early 
invasive that did not show any invasion into the muscle 
layer, and 17 advanced invasive cancers that had invaded 
the muscle layer) and 32 dysplasias (14 mild dysplasias and 
18 moderate-severe dysplasias). Some cancer and dysplastic 
specimens were harvested simultaneously from one patient. 
The histological sections and immunostaining were analyzed 
by a single pathologist without knowledge of clinical data.
Immunohistochemistry for tongue tissues. The frozen tissues 
were cut into 4-µm sections, fixed in 4% paraformaldehyde, 
and treated with 3% hydrogen peroxide in methanol for 10 min 
to block the endogenous peroxidase activity. Immunostaining 
was performed with a mouse monoclonal E-cadherin antibody 
(SC-8426, diluted 1:100 for IHC; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, uSA), or rabbit polyclonal BMI1 anti-
body (T3421, 1:100 for IHC; Cosmo Bio Epitomics, CA, uSA), 
or rabbit polyclonal ZEB1 antibody (SC-25388, 1:100 for IHC; 
Santa Cruz Biotechnology, Inc.) overnight at 4˚C or mouse 
monoclonal vimentin antibody (no. M0725; 1:200 for IHC; 
Dako, Glostrup, Denmark) for 30 min at room temperature. 
After rinsing in phosphate-buffered saline, the sections were 
incubated with biotinylated secondary antibody. Detection 
was performed with diaminobenzidine (DAB) and counter-
stained with Mayer hematoxylin followed by dehydration and 
mounting.
Assessment of immunohistochemical staining. Immuno-
histochemical staining was observed in the parabasal and basal 
cell layer of the normal squamous epithelium, the dysplasias, 
and the outermost layer of cancer cells at the invasive front. 
The semi-quantitative analysis of the stained sections was 
carried out by light-microscopy according to the immunore-
active scoring (IRS) system by Remmele and Stegner (32). 
Sections were examined at a magnification of x400 and the 
staining intensity (SI) was assessed by comparison with 
adjacent normal epithelia, which served as a reference for 
moderate intensity (M). Tumor staining less intense than the 
basal layer of adjacent normal epithelia was classified as weak 
(W), more intense staining as strong intensity (S), and no 
staining as negative (N). When a tumor had different staining 
intensities we assessed 10 random areas and recorded the 
largest area of intensity among these 10 measurements as the 
intensity for that tumor. Based on the percentage of positive 
cells (PP), the samples were classified into five grades: grade 0, 
(0%); grade 1, (0-10%); grade 2, (11-50%); grade 3, (51-80%); 
and grade 4, (81-100%). The product of SI and PP was the IRS. 
The IRS with points from 0 to 12 was adapted to an additional 
3-point IRS classification (Table I).
Laser microdissection. The 8 µm sliced sample was fixed in 
95% ethanol for 5 min, and then washed with 70% ethanol, and 
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stained with the LCM frozen section staining kit (Ambion). 
We procured a few hundred cells from the cancers or dyspla-
sias and the adjacent normal epithelia from 15 samples using 
laser microdissection (PALM MicroBeam; Zeiss, Boston, 
Massachusetts, uSA) (fig. 1A and B). The microdissected 
cells within the cap were covered with buffer and vortexed. 
Total RNA was extracted from each population of laser-micro-
dissected cells.
Reverse transcription-quantitative PCR. Total RNA was 
extracted with the RNeasy Plus Micro kit (qiagen, Valencia, 
CA, uSA), mRNA was reverse transcribed with SuperScript 
VILO Master Mix (Invitrogen-Life Technologies, Carlsbad, 
CA, uSA), and cDNA synthesis was performed. quantitative 
PCR was performed with an ABI PRISM 7500 fast Real-Time 
PCR System (Applied Biosystems).
The amplification profile used was: denaturation at 95˚C 
for 10 min, followed by 50 cycles of denaturation at 95˚C for 
15 sec and annealing at 60˚C for 1 min. The expression levels 
were quantified using the vimentin primer (Hs00185584_m1; 
TaqMan), E-cadherin primer (Hs01023894_m1; TaqMan), 
BMI1 primer (Hs00180411_m1; TaqMan), and ZEB1 primer 
(Hs00232783_m1, TaqMan) (all from Applied Biosystems). 
The geometric mean of the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal control to 
normalize any variability. The comparative cycle threshold 
(CT) method was applied to quantify the relative expression 
levels of mRNAs. The relative amount of each marker was 
calculated using the equation 2-ΔCT where ΔCT = (CTx-CTGAPDH).
Statistical analysis. A comparison of the protein expres-
sion levels according to the IRS was carried out using the 
Kruskal-Wallis and the post hoc Mann-Whitney u tests. 
A comparison of mRNA expression levels was carried out 
using the non-repeated measures ANOVA and post-hoc 
Mann-Whitney u test. The correlation between the expression 
of several biomarkers in the TSCC cells was assessed with the 
Chi-square and fisher's exact tests, and Spearman's correla-
tion. Statistical analyses were performed using modified EZR 
(The R foundation for Statistical Computing, Perugia, Italy) 
software programs. Two-tailed P-values were calculated and 
P<0.05 and <0.01 were considered to indicate a statistically 
significant result.
Results
Protein expression in an in vitro TSCC invasion model. In 
our collagen gel invasion assay, we examined the associa-
tion between protein expression and early invasion of TSCC 
cells (TOSCa-2S and TOSCa-23). Only 2.5% of preinvasive 
cells had a high vimentin expression, but as many as 70.0% 
of invasive cells had high vimentin levels. Seventy-two 
figure 1. (A) Assessment of immunohistochemical staining and (B) specimen before and after laser microdissection. (A) Immunohistochemical protein 
expression levels were observed in the parabasal and basal cell layer of the normal squamous epithelium and dysplasia, in the invasive front of the invaded 
cancer. The semi-quantitative analysis of the stained sections was carried out by light microscopy according to the immunoreactive scoring (IRS) system 
by Remmele and Stegner (32). (B) mRNA expression levels as well as immunohistochemical protein expression were collected from the parabasal and basal 
cell layer of the normal squamous epithelium and dysplasia, in the invasive front of the invaded cancer. Total mRNA was independently extracted from each 
population of laser-microdissected cells.
Table I. Immunoreactive score (IRS) and IRS classification 
scoring systems.
A, Immunoreactive score (IRS)
Percentage of positive cells x intensity of staining, IRS (0-12)
0, No positive cell 0, No color reaction
1, <10% positive cells 1, Mild reaction
2, 10-50% positive cells 2, Moderate reaction
3, 51-80% positive cells 3, Strong reaction
4, >80% positive cells
B, IRS classification scoring systems
IRS-points IRS-classification
0-4 0, Less than normal Negative
5-8 1, Less than normal Negative
9-12 2, More than normal Positive
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percent of preinvasive cells and only 3.6% of invasive cells 
had high E-cadherin expression levels. Sixty-two percent of 
the preinvasive cells and 73.0% of the invasive cells showed 
a high BMI1 expression, and 60.2% of the preinvasive cells 
in addition to 73.5% of the invasive cells had high-ZEB1 
levels (Fig. 2). Protein expression markers were significantly 
different between the preinvasive and invasive cells (P<0.001, 
P<0.01; Table II).
Protein and mRNA expression in vivo using human tissue 
samples. We compared the expression of these proteins 
immunohistochemically among the five groups of samples: 
normal squamous epithelium, mild and moderate-severe 
dysplasia, early invasive and advanced invasive cancer. BMI1 
immunoexpression was mainly detected within the nuclei 
of the normal squamous epithelium and mild dysplasia, but 
was detected in the nuclei and cytoplasm of the majority of 
severe dysplasia and cancer cells. BMI1 high immunoexpres-
sion (IRS-classification, 12) was observed in 84.4% (27/32) 
of the invasive cancers. ZEB1 expression was detected in the 
cytoplasm of the samples and ZEB1-high expression was only 
observed in 50.0% (16/32) of the invasive cancers (fig. 3).
After scoring and assessing the immunohistochemical 
samples, E-cadherin expression was found to be significantly 
decreased in the moderate-severe dysplasia and invasive cancer 
samples compared with the adjacent normal squamous epithe-
lium (P=0.0021, P<0.001, P<0.0001; fig. 4A). Vimentin and 
BMI1 protein expression levels were significantly increased 
in the invasive cancers, including early and advanced samples 
(P=0.0074, P<0.001, P=0.04, 0.0001; fig. 4A). ZEB1 expression 
was significantly increased only in advanced samples (P=0.014; 
fig. 4A), compared with the adjacent normal squamous 
epithelia. using quantitative PCR, E-cadherin mRNA levels 
were significantly decreased in moderate-severe dysplasias 
figure 2. Protein expression of TSCC cells in collagen gel invasion assay. To conduct the collagen gel invasion assay, we used a 3-dimensional collagen gel 
culture. By the fourth week of cell culture, cancer cells were identified with vimentin, E-cadherin, BMI1 and ZEB1 (magnification, x400). TSCC, tongue 
squamous cell carcinoma; H&E, hematoxylin and eosin staining.
figure 3. Immunohistochemical staining of tongue tissues. Immunohistochemical staining was performed with tongue tissue specimens showing the histo-
logical features of normal epithelium, moderate-severe dysplasia and invasive cancer. The representative examples of histology (H&E, hematoxylin and eosin 
staining) and vimentin, E-cadherin, BMI1 and ZEB1 staining are shown (magnfication, x200).
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and the invasive cancers compared with the adjacent normal 
squamous epithelia (P=0.039, P=0.019; fig. 4B). Vimentin, 
BMI1 and ZEB1 mRNA expression levels were significantly 
increased in the invasive samples compared with the adjacent 
normal squamous epithelia (P=0.047, P=0.036, P=0.045; 
fig. 4B).
Elevated levels of BMI1 were accompanied by the down-
regulation of E-cadherin and an upregulation of vimentin at the 
invasive front, demonstrating a significant negative correlation 
between BMI1 and E-cadherin protein and mRNA expres-
sion (P=0.0097; Table III, P=0.018; fig. 5). This result also 
suggested a significant positive correlation between BMI1 and 
vimentin protein and mRNA expression (P=0.035; Table III, 
P=0.0008; Fig. 5). There was also a significant positive corre-
lation between ZEB1 and vimentin mRNA levels, as well as 
between BMI1 and ZEB1 mRNA (P<0.001, P=0.024; fig. 5).
Discussion
EMT is encountered in three distinct biological settings (33). 
The first setting is associated with implantation and embryonic 
gastrulation, which leads to the mesoderm and endoderm, 
as well as to the development and organization of several 
structures. Type 2 EMTs are engaged in the context of inflam-
mation and fibrosis. These EMTs continue to occur overtime 
until infections are removed and the tissue is repaired. Type 
3 EMTs occur in the context of tumor growth and cancer 
progression, when epithelia transform into cancer cells and 
undergo EMT, which enables invasion and metastasis. EMTs 
have E-cadherin transcriptional repression in common, and 
it is worth noting that E-cadherin loss is associated with the 
progression of papilloma to invasive carcinoma (33).
In the present study, we examined the involvement of BMI1 
and ZEB1 in tongue carcinogenesis by comparing E-cadherin 
and vimentin expression levels in vitro and in vivo.
In the TSCC cell invasion assay, we demonstrated that 
downregulation of E-cadherin was observed in 96.4% of the 
invasive TSCC cells, suggesting that they underwent EMT. We 
revealed that the BMI1 and ZEB1 proteins were expressed in 
73% of the invasive TSCC cells compared with 60% of the 
preinvasive TSCC cells. This finding indicates that higher 
levels of BMI1 and ZEB1 expression are associated with the 
EMT program and TSCC cell invasion.
In TSCC tissues, BMI1 protein and mRNA expression 
levels were significantly increased in the invasive cancer 
tissues including early and advanced samples compared with 
adjacent normal squamous epithelia. At the invasive front, 
elevated levels of BMI1 were accompanied by the downregu-
lation of E-cadherin and the upregulation of vimentin. This 
result shows the significant negative correlation between BMI1 
and E-cadherin expression, and the significant positive corre-
lation between BMI1 and vimentin expression. These results 
suggest that BMI1 elevation at the mRNA and protein level is 
involved in the invasion and progression of TSCC. These are 
similar results with previous studies of other epithelial malig-
nancies and support an important role for BMI1 activation in 
the downregulation of E-cadherin and the induction of EMT.
Other studies of these factors have found similar results. 
for example, Song et al demonstrated that Bmi-1 mRNA and 
protein expression levels were found to correlate with the inva-
sion of nasopharyngeal carcinoma (13). Yang et al showed that 
BMI1 is essential for EMT during tumor development in head 
and neck cancer patients (14). Kang et al showed that Bmi-1 
overexpression was observed in preneoplastic oral mucosal 
tissues, which included those with mild, moderate or severe 
epithelial dysplasia (34). The reason for the divergence from 
our results may be due to the different pathophysiology of oral 
squamous cell carcinomas (non-keratinizing vs. keratinizing). 
furthermore, many of the former studies presented small series 
of patients (N=8,10) with oral dysplastic and carcinoma tissue, 
whereas our results included 64 cases. Notably, Häyry et al 
Table III. Correlation of vimentin, E-cadherin and BMI1 
mRNA expressions.
 BMI1 expression
 -----------------------------------------
 Neg Pos P-valuea
 -----------------------------------------
Expression Grade 0 1 2
E-cadherin Neg 3 11 36 0.0097
 Pos 3 8 6
 BMI1 expression
 -----------------------------------------
 Neg Pos P-valuea
 -----------------------------------------
Vimentin Neg 5 14 22 0.035
 Pos 1 5 20
aEstimated by Chi-square test. Neg, negative; Pos, positive.
Table II. Protein expression analysis in the preinvasive and 
invasive cells.
 Vimentin expression
 -------------------------------------------------------------
Cells Positive (%) Negative (%) P-value
Preinvasive 11 (2.5) 426 (97.5) <0.001
Invasive 79 (70.0) 34 (30.0)
 E-cadherin expression
 -------------------------------------------------------------
Preinvasive 334 (72.3) 128 (27.7) <0.001
Invasive 4 (3.6) 107 (96.4)
 BMI1 expression
 -------------------------------------------------------------
Preinvasive 305 (62.4) 184 (37.6) <0.01
Invasive 135 (73.0) 50 (27.0)
 ZEB1 expression
 -------------------------------------------------------------
Preinvasive 240 (60.2) 159 (39.8) <0.01
Invasive 83 (73.5) 30 (26.5)
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showed a significant negative correlation between Bmi-1 
protein expression and the recurrence of tongue cancer (35). 
This divergence from our results may be due to the samples 
used. Häyry et al used 1-mm biopsy punches that only provide 
information about focal points. Our samples provided a view of 
the entire tumor cross-section. Balasubramanian et al reported 
BMI1 expression in the basal and suprabasal keratinocytes 
but not in the surface epithelium (36). Recently, another study 
showed that in the invading front, BMI is highly enriched in 
CSCs, however, those authors found no Bmi-1 expression in 
figure 4. Vimentin, E-cadherin, BMI1 and ZEB1 protein expression according to the (A) IRS and (B) mRNA expressions. (A and B) Vimentin, BMI1 protein 
and mRNA expression levels were significantly increased in invasive cancer, ZEB1 expression was significantly increased in advanced invasive cancer com-
pared with adjacent normal squamous epithelia. E-cadherin protein and mRNA expression levels were significantly decreased in moderate-severe dysplasia 
and invasive cancer compared with adjacent normal squamous epithelia. Dys, dysplasia; Ca, carcinoma; IRS, immunoreactive scoring.
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the cancer cells (37). In the present study, we evaluated BMI1 
protein and mRNA levels in cancer cells at the invasive front.
The overexpression of ZEB1 was observed in colorectal 
and esophageal cancer, suggesting an important role in 
tumorigenesis (28,29). EMT-induced ZEB1 expression was 
also previously reported to be associated with cancer progres-
sion (38). We confirmed that ZEB1 protein expression was 
significantly increased in advanced invasive cancer compared 
with adjacent normal squamous epithelia, consistent with 
previous studies, and confirmed it to be associated with cancer 
progression.
ZEB1 was found to be responsible for the downregulation of 
basal membrane constituents at the invasive front in colorectal 
carcinoma (29), further, it has been shown that in esophageal 
SCC, ZEB1 downregulation by miR-150 suppressed 
E-cadherin repression, vimentin expression, migration ability 
and tumorigenicity (30). In the present study, we identified a 
significant positive correlation between ZEB1 and vimentin 
mRNA expression, but found no significant correlation 
between ZEB1 and E-cadherin expression. A hallmark of 
EMT is the loss of E-cadherin expression; however, ZEB1 
may not suppress E-cadherin itself. We observed a significant 
correlation between ZEB1 and BMI1 mRNA levels, which 
may indicate common regulation of BMI1 and ZEB1.
Recent fidings showed that EMT plays important roles in 
cancer invasion and metastasis by imparting cancer stem-cell 
properties (4,9). One study demonstrated that ZEB1 and 
ZEB2 are key modulators of CSC properties in head and neck 
cancers, including EMT, metastasis and drug resistance (39). 
The results of the present study indicate that the activation of 
BMI1, a stem cell-like marker, is associated with the promotion 
of EMT and invasion in TSCC. furthermore, elevated levels of 
BMI1 were accompanied by the downregulation of E-cadherin 
and upregulation of vimentin, and the elevated levels of ZEB1 
were accompanied by the upregulation of vimentin at the inva-
sive front of TSCCs.
We hypothesized that each of the variety of pathological 
tissues comprising oral cancers have individual roles in carci-
nogenesis. further investigation is needed to elucidate the roles 
and mechanisms of BMI1 and ZEB1 in TSCC. In summary, 
Figure 5. Correlation of the IHC grading of protein expression. A significant negative correlation between BMI1 and E-cadherin expression, and a significant 
positive correlation between BMI1 and vimentin expression is shown. There was a significant positive correlation between ZEB1 and vimentin mRNA expres-
sions, between BMI1 and ZEB1 mRNA expressions.
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our findings show that BMI1 and ZEB1 are important factors 
associated with the promotion of EMT and invasion of TSCC.
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